These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
648 related articles for article (PubMed ID: 34954493)
1. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493 [TBL] [Abstract][Full Text] [Related]
2. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB; Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989 [TBL] [Abstract][Full Text] [Related]
3. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387 [TBL] [Abstract][Full Text] [Related]
4. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh. Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689 [TBL] [Abstract][Full Text] [Related]
6. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program. Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544 [TBL] [Abstract][Full Text] [Related]
7. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol. Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686 [TBL] [Abstract][Full Text] [Related]
8. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA; J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642 [TBL] [Abstract][Full Text] [Related]
9. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984 [TBL] [Abstract][Full Text] [Related]
11. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446 [TBL] [Abstract][Full Text] [Related]
12. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528 [TBL] [Abstract][Full Text] [Related]
13. HCV-HIV co-infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece. Basoulis D; Mastrogianni E; Eliadi I; Papadopoulou M; Psichogiou M HIV Med; 2024 Oct; 25(10):1135-1144. PubMed ID: 39031579 [TBL] [Abstract][Full Text] [Related]
14. Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities. Handanagic S; Broz D; Finlayson T; Kanny D; Wejnert C; Drug Alcohol Depend; 2024 Apr; 257():111251. PubMed ID: 38457965 [TBL] [Abstract][Full Text] [Related]
15. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050 [TBL] [Abstract][Full Text] [Related]
16. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study. Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571 [No Abstract] [Full Text] [Related]
17. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder. Pericot-Valverde I; Heo M; Niu J; Rennert L; Norton BL; Akiyama MJ; Arnsten J; Litwin AH Drug Alcohol Depend; 2022 May; 234():109403. PubMed ID: 35306390 [TBL] [Abstract][Full Text] [Related]
18. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs. Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867 [TBL] [Abstract][Full Text] [Related]
19. Modeling the impact of the COVID-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco. Fraser H; Stone J; Facente SN; Artenie A; Patel S; Wilson EC; McFarland W; Page K; Vickerman P; Morris MD Int J Drug Policy; 2024 Sep; 131():104452. PubMed ID: 38910096 [TBL] [Abstract][Full Text] [Related]
20. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study. Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]